Literature DB >> 33509939

The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention.

Tashbib Khan1, Thomas Kryza1, Nicholas J Lyons1, Yaowu He1, John D Hooper2.   

Abstract

CUB-domain containing protein 1 (CDCP1) is a type I transmembrane glycoprotein that is upregulated in malignancies of the breast, lung, colorectum, ovary, kidney, liver, pancreas, and hematopoietic system. Here, we discuss CDCP1 as an important hub for oncogenic signaling and its key roles in malignant transformation and summarize approaches focused on exploiting it for cancer diagnosis and therapy. Elevated levels of CDCP1 are associated with progressive disease and markedly poorer survival. Predominantly located on the cell surface, CDCP1 lies at the nexus of key tumorigenic and metastatic signaling cascades, including the SRC/PKCδ, PI3K/AKT, WNT, and RAS/ERK axes, the oxidative pentose phosphate pathway, and fatty acid oxidation, making important functional contributions to cancer cell survival and growth, metastasis, and treatment resistance. These findings have stimulated the development of agents that target CDCP1 for detection and treatment of a range of cancers, and results from preclinical models suggest that these approaches could be efficacious and have manageable toxicity profiles. ©2021 American Association for Cancer Research.

Entities:  

Year:  2021        PMID: 33509939     DOI: 10.1158/0008-5472.CAN-20-2978

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.

Authors:  Donglei Ji; Guanglei Shang; Enwei Wei; Yanjie Jia; Chunyu Wang; Qiang Zhang; Lei Zeng
Journal:  Oncogene       Date:  2022-05-05       Impact factor: 9.867

Review 2.  Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.

Authors:  Martijn A van Dam; Floris A Vuijk; Judith A Stibbe; Ruben D Houvast; Saskia A C Luelmo; Stijn Crobach; Shirin Shahbazi Feshtali; Lioe-Fee de Geus-Oei; Bert A Bonsing; Cornelis F M Sier; Peter J K Kuppen; Rutger-Jan Swijnenburg; Albert D Windhorst; Jacobus Burggraaf; Alexander L Vahrmeijer; J Sven D Mieog
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

Review 3.  Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression.

Authors:  Stephan Niland; Andrea Ximena Riscanevo; Johannes Andreas Eble
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

4.  Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.

Authors:  Tahleesa J Cuda; Yaowu He; Thomas Kryza; Tashbib Khan; Brian W Tse; Kamil A Sokolowski; Cheng Liu; Nicholas Lyons; Madeline Gough; Cameron E Snell; David K Wyld; Stephen Rose; Andrew D Riddell; Andrew R L Stevenson; Paul A Thomas; David A Clark; Simon Puttick; John D Hooper
Journal:  Contrast Media Mol Imaging       Date:  2021-09-13       Impact factor: 3.161

5.  Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers.

Authors:  Katelyn L Donahue; Marina Pasca di Magliano
Journal:  J Clin Invest       Date:  2022-02-15       Impact factor: 14.808

Review 6.  The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.

Authors:  Ashna A Kumar; Benjamin J Buckley; Marie Ranson
Journal:  Biomolecules       Date:  2022-01-18

7.  Inhibition of cotranslational translocation by apratoxin S4: Effects on oncogenic receptor tyrosine kinases and the fate of transmembrane proteins produced in the cytoplasm.

Authors:  Weijing Cai; Ranjala Ratnayake; Mengxiong Wang; Qi-Yin Chen; Kevin P Raisch; Long H Dang; Brian K Law; Hendrik Luesch
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-09-08

8.  Overexpression of CDCP1 is Associated with Poor Prognosis and Enhanced Immune Checkpoints Expressions in Breast Cancer.

Authors:  Jinlu Zhao; Jie Mei; Fengxu Wang; Xinyuan Zhao; Yi Ren; Xingyu Zhao; Wang Li; Erli Gao
Journal:  J Oncol       Date:  2022-08-31       Impact factor: 4.501

Review 9.  Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?

Authors:  Christopher Montemagno; Shamir Cassim; Nicolas De Leiris; Jérôme Durivault; Marc Faraggi; Gilles Pagès
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.